Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.28USD
−27.88 MUSD
2.00 MUSD
17.22 M
About Sagimet Biosciences Inc. - Series A
Sector
CEO
David A. Happel
Headquarters
San Mateo
Website
Employees (FY)
10
Founded
2006
FIGI
BBG0020584Y9
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SGMT is 4.44 USD — it has increased by 2.54% in the past 24 hours. Watch Sagimet Biosciences Inc. - Series A stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sagimet Biosciences Inc. - Series A stocks are traded under the ticker SGMT.
Sagimet Biosciences Inc. - Series A is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
SGMT stock is 9.90% volatile and has beta coefficient of 4.86. Track Sagimet Biosciences Inc. - Series A stock price on the chart and check out the list of the most volatile stocks — is Sagimet Biosciences Inc. - Series A there?
SGMT earnings for the last quarter are −0.36 USD per share, whereas the estimation was −0.58 USD resulting in a 37.66% surprise. The estimated earnings for the next quarter are −0.39 USD per share. See more details about Sagimet Biosciences Inc. - Series A earnings.
Sagimet Biosciences Inc. - Series A revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 0 USD.
Yes, you can track Sagimet Biosciences Inc. - Series A financials in yearly and quarterly reports right on TradingView.
SGMT stock has risen by 12.69% compared to the previous week, the month change is a 17.78% fall, over the last year Sagimet Biosciences Inc. - Series A has showed a 71.35% decrease.
SGMT net income for the last quarter is −8.15 M USD, while the quarter before that showed −6.35 M USD of net income which accounts for −28.30% change. Track more Sagimet Biosciences Inc. - Series A financial stats to get the full picture.
Today Sagimet Biosciences Inc. - Series A has the market capitalization of 138.19 M, it has increased by 2.13% over the last week.
No, SGMT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, SGMT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sagimet Biosciences Inc. - Series A stock right from TradingView charts — choose your broker and connect to your account.
SGMT reached its all-time high on Jan 22, 2024 with the price of 20.71 USD, and its all-time low was 2.13 USD and was reached on Nov 13, 2023. View more price dynamics on SGMT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 9, 2024, the company has 10.00 employees. See our rating of the largest employees — is Sagimet Biosciences Inc. - Series A on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sagimet Biosciences Inc. - Series A technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sagimet Biosciences Inc. - Series A stock shows the strong sell signal. See more of Sagimet Biosciences Inc. - Series A technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Sagimet Biosciences Inc. - Series A future price: according to them, SGMT price has a max estimate of 67.00 USD and a min estimate of 26.00 USD. Watch SGMT chart and read a more detailed Sagimet Biosciences Inc. - Series A stock forecast: see what analysts think of Sagimet Biosciences Inc. - Series A and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sagimet Biosciences Inc. - Series A EBITDA is −30.64 M USD, and current EBITDA margin is −1.54 K%. See more stats in Sagimet Biosciences Inc. - Series A financial statements.